Adimab

Adimab is the most successful antibody discovery and engineering company in the industry and the partner of choice for biopharma. Since 2007, we’ve collaborated with global pharma, cutting-edge biotech, and leading academic institutions to generate high-quality therapeutic leads across a wide range of targets and formats.

Our proprietary yeast-based platform enables end-to-end discovery, optimization, and developability assessment, delivering fully human IgGs, HCAbs, multispecifics, and other protein-based modalities, including TCRs, with speed, precision, and reliability.

We have worked on 650+ discovery campaigns and generated 80+ clinical programs created with more than 140 partners. With no internal pipeline, every program reflects our full commitment to our partners’ success.